STAAR Surgical Company reported significant financial improvements in its latest quarterly results, with net sales reaching $93.5 million for the three months ended April 3, 2026, a substantial increase of 119.6% compared to $42.6 million in the same period last year. This growth was primarily driven by strong sales in China, where the company generated $47.4 million, a stark contrast to net returns of $0.9 million in the prior-year period. The gross profit also saw a notable rise, increasing to $68.9 million, resulting in a gross margin of 73.6%, up from 65.8% a year earlier.
The company’s operating income turned positive at $8.0 million, a significant recovery from an operating loss of $57.4 million in the previous year. Net income for the quarter was reported at $5.2 million, or $0.10 per diluted share, compared to a net loss of $54.2 million, or $(1.10) per share, in the same quarter of 2025. This turnaround in profitability was attributed to increased sales, higher gross profit, and reduced operating expenses, particularly in general and administrative costs, which decreased by 30.4% year-over-year.
In terms of operational developments, STAAR Surgical launched its EVO+ ICL in China during the first quarter of 2026, which has been well-received in the market. The company is also focusing on expanding its product line and geographic reach, with plans to manufacture and supply 100% of EVO and EVO+ ICL lenses for China from its Swiss facility by the end of fiscal 2026. The company’s total assets slightly decreased to $451.1 million from $451.7 million at the beginning of the year, while total liabilities also fell to $98.8 million from $107.5 million, indicating improved financial health.
STAAR Surgical's workforce has been adjusted as part of its restructuring efforts, which included leadership realignment and cost reduction initiatives. The company incurred $2.7 million in restructuring charges during the quarter, a significant decrease from $22.7 million in the prior year. The company’s cash and cash equivalents decreased to $131.9 million from $153.2 million, primarily due to front-loaded payments for seasonal bonuses and other expenses. Looking ahead, STAAR Surgical anticipates generating positive cash flow for the remainder of the year, supported by its strong sales performance and ongoing operational improvements.
About STAAR SURGICAL CO
STAAR Surgical designs, manufactures, and sells implantable lenses for eye refractive surgery, primarily focusing on phakic intraocular lenses (ICLs) made from proprietary Collamer material. Its products treat myopia, hyperopia, astigmatism, and presbyopia, serving ophthalmic surgeons worldwide. The company emphasizes minimally invasive, reversible procedures, with a competitive edge in safety, clinical efficacy, and innovation, operating globally with a strong regulatory and intellectual property foundation.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.